Form 8-K - Current report:
SEC Accession No. 0000950170-25-044842
Filing Date
2025-03-26
Accepted
2025-03-26 09:33:04
Documents
18
Period of Report
2025-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jagx-20250326.htm   iXBRL 8-K 71643
2 EX-4.1 jagx-ex4_1.htm EX-4.1 152082
3 EX-4.2 jagx-ex4_2.htm EX-4.2 149162
4 EX-4.3 jagx-ex4_3.htm EX-4.3 149391
5 EX-10.1 jagx-ex10_1.htm EX-10.1 339503
6 EX-10.2 jagx-ex10_2.htm EX-10.2 175033
7 EX-99.1 jagx-ex99_1.htm EX-99.1 20545
8 GRAPHIC img107817981_0.jpg GRAPHIC 87080
  Complete submission text file 0000950170-25-044842.txt   1459729

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT jagx-20250326.xsd EX-101.SCH 24902
20 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20250326_htm.xml XML 4708
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 25770379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)